Insmed, Inc. (INSM) Stock Price
INSMStock
$96.27−41.01%52W
Market Cap$21.02B
P/E—
PEG Ratio1.09
Div yield—
Beta0.83
INSM Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-47.15%
Price vs S&P 500 (4W)-19.11%
PEG Ratio1.09
VGM Score51.55
INSM Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.68 | -$0.06 | +91.21%(+$0.62) | |
| Q1 2026 | -$1.00 | -$0.76 | +23.93%(+$0.24) | |
| Q4 2025 | -$1.17 | -$1.54 | -31.92%(-$0.37) | |
| Q3 2025 | -$1.37 | -$1.75 | -27.80%(-$0.38) | |
| Q2 2025 | -$1.31 | -$1.70 | -29.60%(-$0.39) |
INSM Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.28
4.28
4.27
4.27
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
INSMInsmed, Inc. | F | A | C | 18.5x | 185.8% | 83.5% | — | $96.27 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Insmed, Inc.
Insmed is a biopharmaceutical company with two commercial respiratory products, Arikayce and Brinsupri, which generate revenue primarily from the United States. Its clinical pipeline spans respiratory, immunology, inflammation, and rare neurological disorders, including programs TPIP, INS1148, brensocatib, and INS1201. Pre-clinical research encompasses gene therapy, AI-driven protein engineering, and RNA end-joining technologies.